The Business Year

Search
Close this search box.
Mx23_HE_Tycsa_Patrick

MEXICO - Health & Education

Patrick Troop

Managing Director, Pharma Tycsa

Bio

Patrick Troop is Managing Director of Pharma Tycsa.

"Specifically in public healthcare, there is a great deal of uncertainty regarding the next two years and even after 2024, because Mexico will have presidential elections."

With a full range of logistics services for pharmaceutical companies in Mexico, Pharma Tycsa is ready to play a key role in developing the sector further in light of emerging growth opportunities in the region.

What trends are you seeing in Mexico, specifically in the health industry?

Specifically in public healthcare, there is a great deal of uncertainty regarding the next two years and even after 2024, because Mexico will have presidential elections. Since there have been many changes to the regulations and the players, things are murky. This give us room to truly evaluate where we are going and which markets will we attend to, namely federal, state, or others. We were searching for different niches of business in the pharmaceutical industry to serve our public customers. Today, we have four different lines of businesses: the distribution and compounding of oncology products; distribution compounding; third-party logistics services for the pharmaceutical industry specifically for multinational companies; and state logistics operations for the last mile, a segment of logistics services for public customers. Here, we operate state contracts to do the entire logistics for government customers within their regions.

How do you help international players enter the public health industry?

Within third-party logistics services, we have different models that depend on our customers. We have a portfolio of services to help pharmaceutical companies enter and serve the public market. We have a department of experts on all the regulations and steps needed to submit their products, and we can go all the way to storing their products in our warehouses and delivering them. Pharmaceutical companies are experts in promotions and manufacturing, but they are not experts on logistics, so this is where we come in. That is our core business and is where we add value to our customers.

Why did Pharma Tycsa decide to invest MXN30 million into a distribution center?

Many of the large companies in Mexico left the market for several reasons. We therefore see a great opportunity for the market to be filled. The strategy of Pharma Tycsa from the beginning has been to work with multinational companies rather than local generic manufacturers. The biggest player in that segment was Farmacos Especializados, which closed down. We are ready to capture many of those customers, and given that the only option that they were working with disappeared, we are trying to capture that market now.

What main opportunities for growth have you identified within the logistics industry for pharmaceutical companies?

On the one hand, the logistics practice, which is our core business, will never disappear because manufacturers and pharmaceutical companies will not focus on that activity. Someone will always have to do logistics for either the government or pharmaceutical companies. The only thing we need to do is to be flexible, to understand the dynamics of the industry, and to be prepared to capture and offer our infrastructure in order that the market can respond to these needs. On the other hand, medication and pharmaceuticals are evolving in line with more technology, becoming much more complex, and involving many more biological sources. This will make them more precise and target individual patients more rather than generic symptoms, which will be a major change in the future. Therefore, new infrastructure will be required to handle those products, mainly cold chain, and we have to be ready to adapt to all those needs from the industry and be the first ones to offer such options. All these new biological products will require different traceability options and they can potentially have different side effects for patients. The healthcare and pharmaceutical industry will certainly see new challenges. The coming few years will be extremely interesting. We do not have time to recreate things; we just have to look overseas for the best practices to be implemented in Mexico. Additionally, Mexico will get new products on the market that might be of high quality and low cost. Therefore, there are several opportunities in the market.

ADVERTISEMENT

ADVERTISEMENT

You may also be interested in...

BOHN

MEXICO - Industry

Luis Gerard

Interview

President, Bohn de México/FB Group

MX24_IT_MCM_alejandro

MEXICO - Telecoms & IT

Alejandro Hernández Bringas

Interview

CEO, MCM Telecom

MX24_FI_LIBERTAD_RICARDO

MEXICO - Finance

José Ricardo Merino

Interview

CEO, Libertad Soluciones de Vida

View All interviews

Countries

Countries

Become a sponsor